CN102370964B - Interleukin-1 receptor antagonist protein is preparing the application in preparation for external application to skin - Google Patents
Interleukin-1 receptor antagonist protein is preparing the application in preparation for external application to skin Download PDFInfo
- Publication number
- CN102370964B CN102370964B CN201010254781.9A CN201010254781A CN102370964B CN 102370964 B CN102370964 B CN 102370964B CN 201010254781 A CN201010254781 A CN 201010254781A CN 102370964 B CN102370964 B CN 102370964B
- Authority
- CN
- China
- Prior art keywords
- interleukin
- receptor antagonist
- antagonist protein
- skin
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
The invention discloses interleukin-1 receptor antagonist protein and prepare the application in preparation for external application to skin.Interleukin-1 receptor antagonist protein (ILRa) is prepared into the preparation for external application to skin such as cosmetics and using for local skin, can reaches antiallergic, taking off red, antiinflammatory, the object of the treating skin diseases such as Red blood streak dispelling and facial beautification and skin rejuvenation function.
Description
Technical field
The present invention relates to interleukin-1 receptor antagonist protein and prepare the application in preparation for external application to skin.
Background technology
Interleukin-1 receptor antagonist protein is a kind of protein-based cytokine receptor antagonist being present in human body, by bind interleukin receptor, closes the activity of interleukin specifically.The interleukin-1 receptor antagonist protein that current technique for gene engineering body outer clone is produced, as a kind of injection medicine, is mainly used in the treatment of rheumatoid arthritis.Yet there are no about interleukin-1 receptor antagonist protein is made into preparation for external application to skin, for the report of the disease such as beautifying skin and skin allergy treatment.
Summary of the invention
Interleukin-1 receptor antagonist protein is the object of the present invention is to provide to prepare the application in preparation for external application to skin.
In the present invention, interleukin-1 receptor antagonist protein can make different dosage forms from different substrate respectively.As being prepared into aqueous gels with gel-type vehicle; Or be prepared into Emulsion with emulsion bases, or be mixed with into aqueous solution with water.
As one embodiment of the present invention: the gel-type vehicle of interleukin-1 receptor antagonist protein and external preparation for skin, aqueous solution or emulsion bases are mixed homogeneously, makes the interleukin-1 receptor antagonist protein external preparation that directly can be applied in skin.
As another embodiment of the invention: after interleukin-1 receptor antagonist protein is first made into liposome, then mix with gel-type vehicle, water or emulsion bases, make the product that can be applied in skin.
As a kind of preferred implementation of the present invention: interleukin-1 receptor antagonist protein is first made into lyophilized powder and preserves, mix with the external-use gel prepared or aqueous solution or emulsion bases again before using, the biologic activity of interleukin-1 receptor antagonist protein can be kept so to greatest extent, and the effectiveness of external preparation for skin.
The content of interleukin-1 receptor antagonist protein described in the present invention in external preparation is 10 ~ 500 mcg/ml (micrograms/gram).
Interleukin-1 receptor antagonist protein described in the present invention includes but not limited to recombination human leukopenic-1 receptor antagonist protein or its modified protein.
Gel-type vehicle of the present invention is the aqueous gel substrate containing water-soluble wetting agent, hydrophilic gel and PH regulator.Described water-soluble wetting agent can be selected from one or more the mixing in glycerol, propylene glycol, hyaluronic acid, heparin and aminoacid etc.Described hydrophilic gel can be selected from one or more the mixing in carboxymethyl cellulose, methylcellulose, polyvinylpyrrolidone, gelatin, silicone gum, alginic acid and sodium salt thereof etc.
The present invention has the following advantages:
(1) interleukin-1 receptor antagonist protein (ILRa) be prepared into the preparation for external application to skin such as cosmetics can for local skin use, reach antiallergic, take off red, antiinflammatory, the object of the treating skin diseases such as Red blood streak dispelling and facial beautification and skin rejuvenation function.
(2) the present invention can maintain and retain the maximum biologic activity of interleukin-1 receptor antagonist protein, make it infiltrate skin and play its intrinsic biological effect, but also there is good dermal sensation and hold and stay characteristic, and good wettability, permeability and absorbability.
(3) interleukin-1 receptor antagonist protein is first made into lyophilized powder preservation by the present invention, mix with the external-use gel prepared or aqueous solution or emulsion bases again before using, the biologic activity of interleukin-1 receptor antagonist protein can be kept so to greatest extent, and the effectiveness of external preparation for skin.
Detailed description of the invention
Below in conjunction with experimental example and embodiment, the present invention is set forth, but protection scope of the present invention is not only confined to following examples.Person of an ordinary skill in the technical field, according to content disclosed by the invention, all can realize object of the present invention.
Interleukin-1 receptor antagonist protein described in following examples can adopt and include but not limited to recombination human leukopenic-1 receptor antagonist protein or its modified protein.
Embodiment 1: the aqueous gel containing interleukin-1 receptor antagonist protein and preparation thereof
Use conventional mixing techniques mixing following (A) aqueous gel substrate, and (B) is containing interleukin-1 receptor antagonist protein
Composition by weight percent
A glycerol 5%
Pyrrolidone sodium carboxylate 5%
Hyaluronic acid 0.2%
Acrylate/C10-30 alkyl acrylate cross-linked polymer 0.2%
Allantoin 1.0%
Phenoxyethanol 1.0%
Pure water adds to 100%
B interleukin-1 receptor antagonist protein 50 mcg/ml
Glycerol, pyrrolidone sodium carboxylate, hyaluronic acid, acrylate/C10-30 alkyl acrylate cross-linked polymer, allantoin, phenoxyethanol are dissolved in the water in 55 DEG C and are fully mixed to get raw material A, be cooled to 40 DEG C, add interleukin-1 receptor antagonist protein and with the further stirring and evenly mixing of agitator, then use the lactic acid of 0.1M or triethanolamine to adjust PH to 6.8.It is little that so obtained aqueous gel has viscosity, is used in skin surface and has good dermal sensation, and have fabulous wettability and permeability.
In the present invention, described gel-type vehicle can also be the aqueous gel substrate containing water-soluble wetting agent, hydrophilic gel and PH regulator.Water-soluble wetting agent can be selected from glycerol, propylene glycol, hyaluronic acid, heparin, aminoacid etc.Said hydrophilic gel can be selected from carboxymethyl cellulose, methylcellulose, polyvinylpyrrolidone, gelatin, silicone gum, alginic acid and sodium salt thereof etc.
Embodiment 2:
As different from Example 1: the consumption of interleukin-1 receptor antagonist protein is 10 mcg/ml.
Embodiment 3:
As different from Example 1: the consumption of interleukin-1 receptor antagonist protein is 100 mcg/ml.
Embodiment 4:
As different from Example 1: the consumption of interleukin-1 receptor antagonist protein is 500 mcg/ml.
Embodiment 5: the oil in water emulsion containing interleukin-1 receptor antagonist protein and preparation thereof
Conventional mixing and emulsifying technology is used to prepare the emulsion composition containing following ingredients
Composition by weight percent
A polyethenoxy sorbitan monostearate 2%
Hydrogenated lanolin 5%
Squalene 10%
Cera Flava 5%
Silicone oil 2%
Vitamin e1 %
B glycerol 10%
Allantoin 1.0%
Pure water adds to 100%
C phenoxyethanol 3.0%
Essence is appropriate
Interleukin-1 receptor antagonist protein 50 mcg/ml
Oil phase substrate raw material A is mixed to get after polyethenoxy sorbitan monostearate, hydrogenated lanolin, Squalene, Cera Flava, silicone oil and vitamin E being heated to 90 DEG C of meltings.Pure water heats 95 DEG C, glycerol, allantoin are dissolved and make Aqueous Phase Raw Material B, by oil phase substrate raw material A, the emulsifying of Aqueous Phase Raw Material B two-phase mixtures, be cooled to 40 DEG C, then add the phenoxyethanol in C phase raw material, essence and interleukin-1 receptor antagonist protein and obtain the oil in water emulsion of interleukin-1 receptor antagonist protein with the further stirring and evenly mixing of agitator.Obtained emulsion has good stability, and with contact skin after breakdown of emulsion impel the interleukin-1 receptor antagonist protein in aqueous phase to infiltrate skin as early as possible rapidly.This Emulsion also has good moisturizing function in addition.
Embodiment 6:
As different from Example 5: the consumption of interleukin-1 receptor antagonist protein is 500 mcg/ml.
Embodiment 7:
As different from Example 5: the consumption of interleukin-1 receptor antagonist protein is 10 mcg/ml.
Embodiment 8:
As different from Example 5: the consumption of interleukin-1 receptor antagonist protein be 10 micrograms/gram.
Embodiment 9:
As different from Example 5: the consumption of interleukin-1 receptor antagonist protein be 20 micrograms/gram.
Embodiment 10:
As different from Example 5: the consumption of interleukin-1 receptor antagonist protein be 500 micrograms/gram.
Claims (6)
1. interleukin-1 receptor antagonist protein is preparing the application in preparation for external application to skin:
It is characterized in that, the gel-type vehicle of interleukin-1 receptor antagonist protein and external preparation for skin, aqueous solution or emulsion bases are mixed homogeneously, makes interleukin-1 receptor antagonist protein external preparation;
Or after interleukin-1 receptor antagonist protein is first made into liposome, then mix with gel-type vehicle, water or emulsion bases, make interleukin-1 receptor antagonist protein external preparation;
Or interleukin-1 receptor antagonist protein is first made into lyophilized powder and preserves, mix with the external-use gel prepared or aqueous solution or emulsion bases again before using, make interleukin-1 receptor antagonist protein external preparation.
2. interleukin-1 receptor antagonist protein according to claim 1 is preparing the application in preparation for external application to skin, it is characterized in that, described interleukin-1 receptor antagonist protein is recombination human leukopenic-1 receptor antagonist protein or its modified protein.
3. interleukin-1 receptor antagonist protein according to claim 2 is preparing the application in preparation for external application to skin, it is characterized in that, the content of described interleukin-1 receptor antagonist protein in external preparation is: 50 mcg/ml.
4. interleukin-1 receptor antagonist protein according to claim 3 is preparing the application in preparation for external application to skin, it is characterized in that, described gel-type vehicle is the aqueous gel substrate containing water-soluble wetting agent, hydrophilic gel and PH regulator.
5. interleukin-1 receptor antagonist protein according to claim 4 is preparing the application in preparation for external application to skin, it is characterized in that, described water-soluble wetting agent is one or more the mixing in glycerol, propylene glycol, hyaluronic acid, heparin and aminoacid.
6. interleukin-1 receptor antagonist protein according to claim 4 is preparing the application in preparation for external application to skin, it is characterized in that, described hydrophilic gel can be selected from one or more the mixing in carboxymethyl cellulose, methylcellulose, polyvinylpyrrolidone, gelatin, silicone gum, alginic acid and sodium salt thereof.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010254781.9A CN102370964B (en) | 2010-08-16 | 2010-08-16 | Interleukin-1 receptor antagonist protein is preparing the application in preparation for external application to skin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010254781.9A CN102370964B (en) | 2010-08-16 | 2010-08-16 | Interleukin-1 receptor antagonist protein is preparing the application in preparation for external application to skin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102370964A CN102370964A (en) | 2012-03-14 |
| CN102370964B true CN102370964B (en) | 2015-12-09 |
Family
ID=45790548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010254781.9A Active CN102370964B (en) | 2010-08-16 | 2010-08-16 | Interleukin-1 receptor antagonist protein is preparing the application in preparation for external application to skin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102370964B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1262625A (en) * | 1997-04-10 | 2000-08-09 | 阿吉尼克斯股份有限公司 | Use of lactoferin in treatment of allergen induced disorders |
-
2010
- 2010-08-16 CN CN201010254781.9A patent/CN102370964B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1262625A (en) * | 1997-04-10 | 2000-08-09 | 阿吉尼克斯股份有限公司 | Use of lactoferin in treatment of allergen induced disorders |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102370964A (en) | 2012-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2400576T3 (en) | Compositions of fetal skin cell proteins for the treatment of skin conditions, disorders or diseases and methods for preparing and using them | |
| US20220409513A1 (en) | Cosmetic composition for peel-off-type packs, and method for producing same | |
| WO2010143196A1 (en) | Novel synergistic transparent / translucent hydrogel composition; method of preparing it and a sheet / film made thereform | |
| JP6778220B2 (en) | Application of mussel adhesive protein products in the treatment and prevention of melanin-related diseases | |
| CN103006491A (en) | Biological skin care product for removing growth lines and preparation method thereof | |
| CN107913227A (en) | Containing small yellow ginger without silicone oil hair conditioner and its preparation process | |
| CN103479567B (en) | Epidermal growth factor complex liposome and its preparation method and application | |
| CN105560078A (en) | Preparation method of facial mask containing ossein | |
| CN106389139A (en) | Acne-removing, mark-eliminating and skin-protecting multifunctional preparation and preparation method thereof | |
| KR20160110802A (en) | Cosmetic composition using non-animal nature powder for lifting | |
| KR20060040550A (en) | Agent for promoting secretion of insulin-like growth factor-1 | |
| CN102370964B (en) | Interleukin-1 receptor antagonist protein is preparing the application in preparation for external application to skin | |
| CN111358710A (en) | Moisture-preserving and soothing donkey-hide gelatin face cream and preparation method thereof | |
| CA3030374A1 (en) | Cold-processed self-emulsifying hydroalcoholic gel compositions and methods | |
| TW200927161A (en) | Composition containing granulocyte colony stimulating factor (GCSF) for hair growth | |
| CN100562306C (en) | Contain the biological beauty skin care item of body keratinized cell growth factor-2 and the preparation method of recombinant human keratinized cell growth factor-2 | |
| JP3045613B2 (en) | Hair restoration cosmetics | |
| CN106726672A (en) | A kind of cosmetic composition | |
| JP5171752B2 (en) | Topical skin preparation | |
| Tarigan et al. | Extraction Of Functionally Active Collagen From Salmon Fish As Formulation Of Clay Mask | |
| JP3827259B2 (en) | Keratinization promoter | |
| JP3712673B2 (en) | Gel composition and oil-in-water (O / W) type composition | |
| KR102176832B1 (en) | A microparticle comprising hedgehog protein and biocompatible material and a composition for preventing or treating hair loss comprising the same | |
| JP4194264B2 (en) | Anal skin preparation | |
| JP2004250395A (en) | Bioactive composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230427 Address after: 620031 New Area of Meishan Economic Development Zone, Chengdu, Sichuan Province Patentee after: Sichuan peptide beauty Biotechnology Co.,Ltd. Address before: No. 2, 6th Floor, Unit 3, Building 2, No. 7 Yulin East Road, Wuhou District, Chengdu City, Sichuan Province, 610041 Patentee before: Li Xingde |